4.6 Article

Intracellular glutathione content influences the sensitivity of lung cancer cell lines to methylseleninic acid

期刊

MOLECULAR CARCINOGENESIS
卷 51, 期 4, 页码 303-314

出版社

WILEY-BLACKWELL
DOI: 10.1002/mc.20781

关键词

methylseleninic acid; glutathione; apoptosis; cell cycle; lung cancer cell lines

资金

  1. Natural Science Foundation of China [30670922]
  2. Major Project of Tianjin Sci-Tech Support Program [07SYSYSF05000]
  3. Key Project of Tianjin Sci-Tech Support Program [06YFSZSF05300]

向作者/读者索取更多资源

The synthetic selenium compound methylseleninic acid (MSA) is a direct precursor of active methylselenol and appears to be the best candidate for studies on the mechanisms of selenium cancer prevention and therapy in vitro. Reduced glutathione (GSH) is critical to MSA metabolism, in addition to being a protective antioxidant which scavenges reactive oxygen species (ROS) and maintains the stability of intracellular redox status. In this study, we demonstrated that MSA has an anticancer effect in the human lung cancer cell lines L9981 and 95D using growth inhibition detection, cell-cycle analysis, and apoptosis detection. We examined the role of intracellular GSH content and detected the ROS induced by MSA by fluorescence microscopy, and we used flow cytometry to quantify the ROS induced by pretreatment and co-treatment with N-acetylcysteine (NAC) and MSA. We also confirmed oxidative stress in MSA-induced apoptosis. MSA inhibited lung cancer cell lines L9981 and 95-D growth significantly, induced cell-cycle arrest in the G1 phase and induced apoptosis. Compared to the control group, MSA significantly decreased intracellular GSH content in L9981 cells at higher concentrations of MSA (5 and 7.5 mu M), while the intracellular GSH level was also dramatically decreased in L9981 cells treated with 5 mu M MSA at different time points of 12- and 24-h (decreased to about 50% and 20% of the control, respectively). Pretreatment with either NAC (GSH synthesis precursor) or buthionine sulfoximine (BSO, GSH synthesis inhibitor) in L9981 cells significantly inhibited the anti-proliferative effect of MSA. MSA induced the generation of ROS, which was significantly reduced by NAC pretreatment. Furthermore, we also confirmed these results in another lung cancer cell line 95-D. These results suggest that generation of ROS may be essential for the induction of oxidative stress and apoptosis by MSA in L9981 and 95-D lung cancer cells. The balance between oxidative stress induced by MSA and the antioxidant effect exerted by intracellular GSH content may determine the ultimate outcome after MSA treatment. Mol. Carcinog. (C) 2011 Wiley Periodicals, Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer

Chengfei Liu, Wei Lou, Yezi Zhu, Joy C. Yang, Nagalakshmi Nadiminty, Nilesh W. Gaikwad, Christopher P. Evans, Allen C. Gao

CANCER RESEARCH (2015)

Article Oncology

Antiandrogens inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer

Yezi Zhu, Chengfei Liu, Cameron Armstrong, Wei Lou, Amandeep Sandher, Allen C. Gao

CLINICAL CANCER RESEARCH (2015)

Article Endocrinology & Metabolism

Niclosamide Suppresses Cell Migration and Invasion in Enzalutamide Resistant Prostate Cancer Cells via Stat3-AR Axis Inhibition

Chengfei Liu, Wei Lou, Cameron Armstrong, Yezi Zhu, Christopher P. Evans, Allen C. Gao

PROSTATE (2015)

Article Oncology

Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer

Chengfei Liu, Cameron M. Armstrong, Wei Lou, Alan Lombard, Christopher P. Evans, Allen C. Gao

MOLECULAR CANCER THERAPEUTICS (2017)

Article Oncology

Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer

Chengfei Liu, Cameron Armstrong, Yezi Zhu, Wei Lou, Allen C. Gao

ONCOTARGET (2016)

Article Oncology

Upregulation of glucose metabolism by NF-κB2/p52 mediates enzalutamide resistance in castration-resistant prostate cancer cells

Yuanyuan Cui, Nagalakshmi Nadiminty, Chengfei Liu, Wei Lou, Chad T. Schwartz, Allen C. Gao

ENDOCRINE-RELATED CANCER (2014)

Article Oncology

Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model

Sifeng Qu, Kendric Wang, Hui Xue, Yuwei Wang, Rebecca Wu, Chengfei Liu, Allen C. Gao, Peter W. Gout, Colin C. Collins, Yuzhuo Wang

MOLECULAR ONCOLOGY (2014)

Article Endocrinology & Metabolism

Inhibition of Constitutively Active Stat3 Reverses Enzalutamide Resistance in LNCaP Derivative Prostate Cancer Cells

Chengfei Liu, Yezi Zhu, Wei Lou, Yuanyuan Cui, Christopher P. Evans, Allen C. Gao

PROSTATE (2014)

Article Endocrinology & Metabolism

Interleukin-6 induces neuroendocrine differentiation (NED) through suppression of RE-1 silencing transcription factor (REST)

Yezi Zhu, Chengfei Liu, Yuanyuan Cui, Nagalakshmi Nadiminty, Wei Lou, Allen C. Gao

PROSTATE (2014)

Article Multidisciplinary Sciences

Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer

Chengfei Liu, Wei Lou, Joy C. Yang, Liangren Liu, Cameron M. Armstrong, Alan P. Lombard, Ruining Zhao, Onika D. V. Noel, Clifford G. Tepper, Hong-Wu Chen, Marc Dall'Era, Christopher P. Evans, Allen C. Gao

NATURE COMMUNICATIONS (2018)

Article Oncology

AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer

Chengfei Liu, Joy C. Yang, Cameron M. Armstrong, Wei Lou, Liangren Liu, Xiaomin Qiu, Binhao Zou, Alan P. Lombard, Leandro S. D'Abronzo, Christopher P. Evans, Allen C. Gao

MOLECULAR CANCER THERAPEUTICS (2019)

Article Oncology

Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment

Shu Ning, Chengfei Liu, Wei Lou, Joy C. Yang, Alan P. Lombard, Leandro S. D'Abronzo, Neelu Batra, Ai-Ming Yu, Amy R. Leslie, Masuda Sharifi, Christopher P. Evans, Allen C. Gao

Summary: Next-generation antiandrogen drugs improve survival and quality of life in advanced prostate cancer patients, but resistance to these drugs is not well understood. This study found that the Wnt5a/FZD2 signaling pathway plays a critical role in promoting enzalutamide resistance, and targeting this pathway could be a potential therapy for advanced prostate cancer.

MOLECULAR CANCER THERAPEUTICS (2022)

Article Oncology

Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment

Pengfei Xu, Joy C. Yang, Bo Chen, Christopher Nip, Jonathan E. Van Dyke, Xiong Zhang, Hong-Wu Chen, Christopher P. Evans, William J. Murphy, Chengfei Liu

Summary: This study investigated the mechanisms underlying the failure of atezolizumab and enzalutamide combination treatment in castration-resistant prostate cancer. The researchers found that enzalutamide-resistant prostate cancer cells promote immunosuppressive signaling, which may contribute to the reduced efficacy of immune checkpoint inhibitors in these patients.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Article Oncology

Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate Cancer

Zachary A. Schaaf, Shu Ning, Amy R. Leslie, Masuda Sharifi, Xianrui Han, Cameron Armstrong, Wei Lou, Alan P. Lombard, Chengfei Liu, Allen C. Gao

Summary: Treatment resistance is a common challenge in castration-resistant prostate cancer. This study examines the resistance patterns of different therapeutic classes and emphasizes the importance of rational drug sequencing in treatment. The findings reveal distinct cross-resistance characteristics among different resistant cell sublines and provide insights into the underlying mechanisms of resistance.

CANCERS (2023)

Meeting Abstract Oncology

Biological evaluation of a novel AKR1C3 inhibitor in patient-derived prostate cancer cell line and xenograft models

Joy C. Yang, Shu Ning, Hans Adomat, Martin Gleave, Allen Gao, Christopher P. Evans, Chengfei Liu

CANCER RESEARCH (2022)

暂无数据